BioCentury
ARTICLE | Company News

Ahead of ESMO data, Clovis' Rubraca dubbed a breakthrough for prostate cancer

October 2, 2018 7:01 PM UTC

Clovis Oncology Inc. (NASDAQ:CLVS) gained $2.25 to $31.39 on Tuesday after it said FDA granted breakthrough therapy designation for Rubraca rucaparib to treat metastatic castration resistant prostate cancer. The designation was based on initial data from the Phase II TRITON2 study, which are to be presented at the European Society for Medical Oncology (ESMO) meeting this month in Munich.

The designation is for adult patients with BRCA1/2-mutated metastatic CRPC who have received at least one prior androgen receptor-directed therapy and taxane-based chemotherapy...

BCIQ Company Profiles

Clovis Oncology Inc.